ha14-1 has been researched along with Duncan Disease in 1 studies
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Srimatkandada, P | 1 |
| Loomis, R | 1 |
| Carbone, R | 1 |
| Srimatkandada, S | 1 |
| Lacy, J | 1 |
1 other study available for ha14-1 and Duncan Disease
| Article | Year |
|---|---|
Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Topics: Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Caspases; Cell Line, Transformed; Cell Proliferat | 2008 |